Stratified high-throughput screening sets enable flexible screening strategies from a single plated collection

Journal of Biomolecular Screening

Volumn 19, Issue 3, 2014, Pages 369-378

  Nissink, J Willem M ^a   Schmitt, Stefan ^b   Blackburn, Sam ^a   Peters, Stephen ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

cumulative screen set; diverse subsets; high throughput screening; layered plating design; plating design; screening deck design; stratification

Indexed keywords

ARTICLE; COMPUTER MODEL; COMPUTER SIMULATION; COST CONTROL; DRUG INDUSTRY; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; VALIDATION STUDY;

CUMULATIVE SCREEN SET; DIVERSE SUBSETS; HIGH-THROUGHPUT SCREENING; LAYERED PLATING DESIGN; PLATING DESIGN; SCREENING DECK DESIGN; STRATIFICATION;

ALGORITHMS; COMPUTER SIMULATION; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES;

EID: 84893868687     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113498933     Document Type: Article

References (20)

1. Paul S. M., Mytelka D. S., Dunwiddie C. T., et al. How to Improve R&D Productivity: The Pharmaceutical Industry's Grand Challenge. Nat. Rev. Drug Disc. 2010 ; 9: 203-214
2. Fox S., Farr-Jones S., Sopchak L., et al. High-Throughput Screening: Update on Practices and Success. J. Biomol. Screen. 2006 ; 11: 864-869
3. Mayr L. M., Bojanic D. Novel Trends in High-Throughput Screening. Curr. Opin. Pharmacol. 2009 ; 9: 580-588
4. Mayr L. M., Fuerst P. The Future of High-Throughput Screening. J. Biomol. Screen. 2008 ; 13: 443-448
5. Pereira D., Williams J. Origin and Evolution of High Throughput Screening. Br. J. Pharmacol. 2007 ; 152: 53-61
6. Bakken G., Boehm M., Bell A., et al. Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy. J. Chem. Inf. Model. 2012 ; 52: 2937-2949
7. Greene J. Minimizing Assays - Increasing Returns. Biosci. Technol. Instrum. Syst. 2006 ; 9: 18-19
8. Blomberg N., Cosgrove D. A., Kenny P. W., et al. Design of Compound Libraries for Fragment Screening. J. Comput. Aided Mol. Des. 2009 ; 23: 513-525
9. Dobson C. M. Chemical Space and Biology. Nature. 2004 ; 432: 824-828
10. Baell J. B., Holloway G. A. New Substructure Filters for Removal of Pan-Assay Interference Compounds from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem. 2010 ; 53: 2719-2740
11. Bruns R. F., Watson I. A. Rules for Identifying Potentially Reactive or Promiscuous Compounds. J. Med. Chem 55. 2012 ;: 9763-9772
12. Roche O., Schneider P., Zuegge J., et al. Development of a Virtual Screening Method for Identification of "Frequent Hitters" in Compound Libraries. J. Med. Chem. 2002 ; 45: 137-142
13. Sassano M. F., Doak A. K., Roth B. L., et al. Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors. J. Med. Chem. 2013 ; 56: 2406-2414
14. Thorne N., Auld D. S., Inglese J. Apparent Activity in High-Throughput Screening: Origins of Compound-Dependent Assay Interference. Curr. Opin. Chem. Biol. 2010 ; 14: 315-324
15. McGovern S. L., Caselli E., Grigorieff N., et al. Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening. J. Med. Chem. 2002 ; 45: 1712-1722
16. Habig M., Blechschmidt A., Dressler S., et al. Efficient Elimination of Nonstoichiometric Enzyme Inhibitors from HTS Hit Lists. J. Biomol. Screen. 2009 ; 14: 679-689
17. Jadhav A., Ferreira R. S., Klumpp C., et al. Quantitative Analyses of Aggregation, Autofluorescence, and Reactivity Artifacts in a Screen for Inhibitors of a Thiol Protease. J. Med. Chem. 2010 ; 53: 37-51
18. Johnston P. A., Soares K. M., Shinde S. N., et al. Development of a 384-Well Colorimetric Assay to Quantify Hydrogen Peroxide Generated by the Redox Cycling of Compounds in the Presence of Reducing Agents. Assay Drug Dev. Technol. 2008 ; 6: 505-518
19. Chuprina A., Lukin O., Demoiseaux R., et al. Drug- and Lead-Likeness, Target Class, and Molecular Diversity Analysis of 7.9 Million Commercially Available Organic Compounds Provided by 29 Suppliers. J. Chem. Inf. Model. 2010 ; 50: 470-479
20. Provis J. Compound Management and Enhancement Activities at AstraZeneca. J. Lab. Autom. 2005 ; 10: 124-129